County of Santa Clara
County of Santa Clara was paid $94.75M by Medicaid between Jan 2018 and Dec 2024, across 911 billing codes. Its largest line is 0450, Emergency room services — 6.7% of everything it billed.
33Billing provider infoCOUNTY OF SANTA CLARA
SAN JOSE, CA 95128
SAN JOSE, CA 95128
33aNPI1063406551assigned 09/09/2005
33bProvider typeCase Manager/Care Coordinator
28Total paid$94.75M
24GClaims7,181,461
24DCodes billed911
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Manager/Care Coordinator providers in California
Rank by total paid#14 of 435
Median peer was paid$2.89M
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LORENZ, PAUL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 775,572 | $13.47M | |
| 2019 | 896,136 | $15.30M | |
| 2020 | 739,577 | $8.59M | |
| 2021 | 1,117,341 | $17.22M | |
| 2022 | 1,149,168 | $16.73M | |
| 2023 | 1,255,198 | $11.09M | |
| 2024incomplete | 1,248,469 | $12.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 6.7% | 272,260 | 237,619 | $6.32M |
| 0121 | 6.2% | 6,599 | 5,852 | $5.83M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.4% | 155,941 | 135,448 | $4.14M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.2% | 1,691 | 1,338 | $3.01M |
| 0129 | 2.5% | 4,599 | 4,120 | $2.34M | |
| 99199 | Unlisted special service, procedure or report | 2.2% | 46,060 | 39,046 | $2.10M |
| J9299 | Injection, nivolumab, 1 mg | 2.1% | 1,177 | 755 | $1.98M |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 2.0% | 19,144 | 17,934 | $1.89M |
| Z7502 | 1.9% | 47,478 | 45,591 | $1.78M | |
| 0002A | 1.8% | 43,705 | 43,703 | $1.74M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 21,936 | 21,463 | $1.71M |
| 0001A | 1.6% | 40,485 | 40,485 | $1.54M |
899 more codes
| 0111 | 1.6% | 1,354 | $1.53M | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 26,762 | $1.53M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 34,266 | $1.52M |
| 0123 | 1.5% | 1,329 | $1.46M | |
| 0206 | 1.3% | 1,843 | $1.23M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.3% | 4,237 | $1.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 37,519 | $1.10M |
| 90378 | 1.1% | 646 | $1.07M | |
| J0897 | Injection, denosumab, 1 mg | 1.1% | 3,588 | $1.07M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 102,509 | $1.04M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.1% | 803 | $1.01M |
| 0510 | 1.0% | 382,515 | $986K | |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 469 | $893K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 303,444 | $888K |
| Z7500 | <1% | 23,619 | $811K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 18,394 | $753K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,939 | $708K |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 861 | $703K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37,452 | $630K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21,797 | $622K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 4,673 | $595K |
| 80051 | <1% | 210,127 | $565K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,865 | $558K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 643 | $549K |
| J9312 | Injection, rituximab, 10 mg | <1% | 535 | $531K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,948 | $523K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 28,323 | $519K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 10,574 | $516K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 832 | $511K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 38,242 | $510K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 37,884 | $501K |
| 0012A | <1% | 12,554 | $468K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 19,015 | $464K |
| Z9725 | <1% | 10,771 | $463K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47,345 | $463K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15,037 | $457K |
| 0004A | <1% | 11,301 | $451K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 20,008 | $430K |
| 80053 | Comprehensive metabolic panel | <1% | 80,025 | $427K |
| 87631 | <1% | 14,565 | $409K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 39,237 | $407K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,991 | $403K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 22,154 | $397K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 242 | $379K |
| 0064A | <1% | 9,218 | $365K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 21,939 | $365K |
| 0054A | <1% | 9,346 | $359K | |
| 80076 | <1% | 144,919 | $346K | |
| 0011A | <1% | 10,128 | $341K | |
| 0072A | <1% | 8,471 | $338K | |
| 71045 | Radiologic examination, chest; single view | <1% | 45,005 | $335K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,572 | $331K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,742 | $326K |
| 86481 | <1% | 19,946 | $324K | |
| 0360 | <1% | 37,009 | $323K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 26,450 | $312K |
| 99284 | Emergency room visit (serious) | <1% | 5,466 | $299K |
| 0071A | <1% | 7,203 | $286K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,866 | $281K |
| 82565 | <1% | 229,609 | $281K | |
| 0202 | <1% | 650 | $279K | |
| 77386 | <1% | 5,092 | $278K | |
| 81513 | <1% | 7,839 | $277K | |
| 0456 | <1% | 42,965 | $271K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 1,263 | $265K |
| 84484 | <1% | 65,035 | $262K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12,807 | $260K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 21,885 | $259K |
| 82947 | <1% | 229,153 | $244K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 66,228 | $241K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 4,731 | $240K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18,003 | $239K |
| 97750 | <1% | 34,766 | $238K | |
| 0270 | <1% | 292,867 | $232K | |
| 0124A | <1% | 5,688 | $223K | |
| 99283 | Emergency room visit (moderate) | <1% | 5,116 | $222K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,087 | $222K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 9,575 | $216K |
| 83690 | <1% | 65,507 | $213K | |
| 84520 | <1% | 211,583 | $208K | |
| 93971 | <1% | 6,239 | $206K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,936 | $204K |
| 81001 | <1% | 137,055 | $199K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 43,769 | $196K |
| 99285 | Emergency room visit (most serious) | <1% | 1,478 | $194K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 16,995 | $194K |
| 0361 | <1% | 53,474 | $191K | |
| 76830 | Ultrasound, transvaginal | <1% | 8,260 | $191K |
| 71250 | <1% | 5,133 | $186K | |
| 70486 | <1% | 3,682 | $184K | |
| 0214 | <1% | 138 | $175K | |
| 93970 | <1% | 3,939 | $175K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,305 | $173K |
| 87481 | <1% | 8,373 | $173K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 217 | $166K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 725 | $165K |
| 0122 | <1% | 1,565 | $164K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,226 | $162K |
| 76801 | <1% | 5,498 | $161K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,969 | $159K |
| 83880 | <1% | 16,872 | $158K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,458 | $155K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 193 | $153K |
| 97139 | <1% | 119,395 | $153K | |
| 0031A | <1% | 3,752 | $149K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 24,642 | $146K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 2,775 | $146K |
| 77066 | Tomosynthesis, mammo | <1% | 5,488 | $144K |
| 80061 | Lipid panel | <1% | 60,470 | $140K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 79,553 | $139K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,346 | $137K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 3,984 | $136K |
| 96367 | <1% | 9,152 | $136K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 6,507 | $125K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 596 | $123K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 1,170 | $121K |
| 73610 | <1% | 10,650 | $111K | |
| 76641 | <1% | 5,548 | $108K | |
| 81025 | <1% | 35,972 | $105K | |
| 73630 | <1% | 12,016 | $105K | |
| 86803 | <1% | 25,142 | $105K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,502 | $104K |
| 87506 | <1% | 1,488 | $103K | |
| 96415 | <1% | 9,347 | $102K | |
| 74178 | <1% | 1,987 | $100K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,123 | $100K |
| 87077 | <1% | 45,105 | $99K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,455 | $98K |
| J3490 | Unclassified drugs | <1% | 50,995 | $97K |
| 73030 | <1% | 9,330 | $97K | |
| 70496 | <1% | 1,514 | $95K | |
| 0052A | <1% | 2,395 | $95K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 4,965 | $94K |
| Z7610 | <1% | 32,487 | $92K | |
| 77080 | <1% | 5,075 | $91K | |
| 96417 | <1% | 6,469 | $91K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 3,753 | $90K |
| 73110 | <1% | 8,239 | $90K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 469 | $89K |
| 87088 | <1% | 43,547 | $89K | |
| 83735 | <1% | 45,004 | $88K | |
| J9041 | Injection, bortezomib, 0.1 mg | <1% | 792 | $88K |
| 76770 | <1% | 4,386 | $86K | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 782 | $86K |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | <1% | 327 | $85K |
| 72131 | <1% | 1,806 | $84K | |
| 92587 | <1% | 7,004 | $84K | |
| 72141 | <1% | 1,141 | $84K | |
| 70498 | <1% | 1,531 | $82K | |
| 0134A | <1% | 2,112 | $80K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,776 | $80K |
| 77065 | Tomosynthesis, mammo | <1% | 4,103 | $79K |
| 70491 | <1% | 1,421 | $79K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 1,362 | $79K |
| 77412 | <1% | 5,111 | $79K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,546 | $79K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 8,473 | $79K |
| 93017 | <1% | 8,011 | $78K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,037 | $75K |
| 73130 | <1% | 6,737 | $75K | |
| 90715 | <1% | 5,431 | $74K | |
| 77300 | <1% | 1,240 | $73K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,087 | $73K |
| 83605 | <1% | 16,478 | $73K | |
| 82274 | <1% | 36,781 | $71K | |
| 74170 | <1% | 1,775 | $71K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,180 | $69K |
| 87040 | <1% | 15,929 | $68K | |
| 85610 | <1% | 58,313 | $68K | |
| 73502 | <1% | 4,363 | $68K | |
| 87340 | <1% | 19,525 | $67K | |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | <1% | 41 | $67K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,957 | $66K |
| 93243 | <1% | 1,178 | $65K | |
| 86480 | <1% | 5,386 | $65K | |
| 76536 | <1% | 5,053 | $64K | |
| 72100 | <1% | 5,585 | $63K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,355 | $61K |
| 73562 | <1% | 7,133 | $61K | |
| 87507 | <1% | 463 | $60K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,047 | $59K |
| 97597 | <1% | 3,670 | $58K | |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | <1% | 329 | $58K |
| 73080 | <1% | 5,616 | $57K | |
| 86780 | <1% | 17,194 | $56K | |
| 85027 | <1% | 34,800 | $56K | |
| 93226 | <1% | 4,756 | $56K | |
| 86235 | <1% | 5,740 | $55K | |
| 86850 | <1% | 15,685 | $55K | |
| 96411 | <1% | 3,567 | $55K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 541 | $55K |
| 87209 | <1% | 5,334 | $55K | |
| 77334 | <1% | 985 | $54K | |
| 0051A | <1% | 1,328 | $53K | |
| 84702 | <1% | 14,566 | $52K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,601 | $51K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,458 | $51K |
| 94726 | <1% | 4,135 | $50K | |
| 77014 | <1% | 3,387 | $49K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,254 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,815 | $49K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,422 | $48K |
| 73221 | <1% | 879 | $47K | |
| 82077 | <1% | 7,981 | $47K | |
| 76870 | <1% | 2,725 | $47K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,994 | $45K |
| 99070 | <1% | 64,401 | $45K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,063 | $44K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,026 | $44K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,519 | $44K |
| 0760 | <1% | 1,471 | $44K | |
| 93225 | <1% | 4,757 | $43K | |
| 92134 | <1% | 17,479 | $43K | |
| 77336 | <1% | 3,710 | $43K | |
| 74183 | <1% | 919 | $42K | |
| 92250 | <1% | 15,701 | $42K | |
| 74174 | <1% | 539 | $42K | |
| 85730 | <1% | 19,570 | $41K | |
| 74018 | <1% | 4,470 | $41K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 2,760 | $41K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 865 | $40K |
| 94729 | <1% | 4,180 | $40K | |
| 97802 | <1% | 3,095 | $40K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 1,804 | $39K |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 827 | $39K |
| 77301 | <1% | 228 | $39K | |
| 96416 | <1% | 1,879 | $38K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,521 | $38K |
| Q3014 | Telehealth originating site facility fee | <1% | 7,800 | $38K |
| 87081 | <1% | 15,909 | $38K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 338 | $37K |
| 73564 | <1% | 2,842 | $37K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,860 | $37K |
| 73590 | <1% | 4,287 | $37K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,397 | $37K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,063 | $37K |
| 94060 | <1% | 2,422 | $37K | |
| 86706 | <1% | 10,866 | $36K | |
| 73560 | <1% | 4,899 | $36K | |
| 99000 | <1% | 19,857 | $35K | |
| 72197 | <1% | 515 | $35K | |
| 0721 | <1% | 6,467 | $35K | |
| 95811 | <1% | 622 | $35K | |
| 0127 | <1% | 35 | $34K | |
| 82962 | <1% | 22,984 | $34K | |
| 92570 | <1% | 641 | $33K | |
| 84439 | <1% | 18,238 | $33K | |
| 72170 | <1% | 3,868 | $32K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,701 | $31K |
| 84460 | <1% | 41,070 | $31K | |
| 73090 | <1% | 3,780 | $31K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 15,347 | $31K |
| 86140 | <1% | 22,444 | $31K | |
| 83970 | <1% | 3,945 | $30K | |
| 96112 | <1% | 184 | $30K | |
| 84703 | <1% | 19,719 | $30K | |
| 87186 | <1% | 17,538 | $29K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,336 | $29K |
| 82728 | <1% | 16,620 | $29K | |
| 90677 | <1% | 548 | $29K | |
| 97799 | <1% | 11,640 | $29K | |
| 97116 | <1% | 2,859 | $29K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,391 | $29K |
| 86300 | <1% | 5,901 | $29K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 474 | $28K |
| 0082A | <1% | 687 | $27K | |
| 87177 | <1% | 6,046 | $27K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 2,870 | $27K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 286 | $27K |
| 87536 | <1% | 1,831 | $27K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,710 | $27K |
| 82570 | <1% | 36,105 | $26K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 1,504 | $26K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 2,382 | $26K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,621 | $26K |
| 84153 | <1% | 7,694 | $26K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 383 | $25K |
| 80305 | <1% | 3,861 | $25K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,700 | $24K |
| 77295 | <1% | 138 | $24K | |
| 86901 | <1% | 15,710 | $24K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 10,556 | $23K |
| 86900 | <1% | 15,732 | $23K | |
| 85379 | <1% | 5,243 | $23K | |
| G0378 | Hospital observation service, per hour | <1% | 2,449 | $23K |
| 72040 | <1% | 2,498 | $23K | |
| 86704 | <1% | 5,508 | $23K | |
| 0038U | <1% | 16,117 | $23K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 5,364 | $22K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 468 | $22K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 3,083 | $22K |
| 0154A | <1% | 550 | $22K | |
| 71101 | <1% | 1,352 | $22K | |
| 73140 | <1% | 3,533 | $22K | |
| 82378 | <1% | 4,872 | $22K | |
| 97165 | <1% | 2,609 | $22K | |
| 93922 | <1% | 2,085 | $21K | |
| 87116 | <1% | 4,295 | $21K | |
| 95782 | <1% | 131 | $21K | |
| 88341 | <1% | 2,062 | $21K | |
| 84403 | <1% | 3,978 | $21K | |
| 90739 | <1% | 674 | $21K | |
| 92579 | <1% | 2,935 | $20K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,076 | $20K |
| 0710 | <1% | 15,234 | $20K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,221 | $20K |
| 83516 | <1% | 5,254 | $20K | |
| 72128 | <1% | 430 | $20K | |
| J2796 | Injection, romiplostim, 10 micrograms | <1% | 168 | $20K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,542 | $20K |
| 92567 | <1% | 5,808 | $20K | |
| 82550 | <1% | 10,389 | $20K | |
| 93880 | <1% | 810 | $20K | |
| 84450 | <1% | 21,818 | $20K | |
| 0949 | <1% | 8,860 | $19K | |
| 59025 | Fetal non-stress test | <1% | 5,694 | $19K |
| 95819 | <1% | 1,649 | $19K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 3,092 | $19K |
| 82803 | <1% | 3,222 | $19K | |
| 83550 | <1% | 15,565 | $19K | |
| 96401 | <1% | 3,914 | $18K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 9,741 | $18K |
| 73552 | <1% | 1,881 | $18K | |
| 82105 | <1% | 2,043 | $18K | |
| 72158 | <1% | 118 | $18K | |
| 86682 | <1% | 1,724 | $18K | |
| 0034A | <1% | 444 | $18K | |
| 93247 | <1% | 2,730 | $17K | |
| 87905 | <1% | 4,003 | $17K | |
| 87556 | <1% | 2,342 | $17K | |
| 97803 | <1% | 1,601 | $17K | |
| 83655 | <1% | 5,137 | $17K | |
| 86160 | <1% | 4,952 | $17K | |
| 92582 | <1% | 1,431 | $17K | |
| 92557 | <1% | 1,623 | $17K | |
| 87015 | <1% | 4,075 | $17K | |
| 80047 | <1% | 4,172 | $16K | |
| 92523 | <1% | 464 | $16K | |
| 85651 | <1% | 19,928 | $16K | |
| 84100 | <1% | 16,290 | $16K | |
| 91320 | <1% | 123 | $16K | |
| 96409 | <1% | 1,793 | $16K | |
| 88112 | <1% | 2,436 | $16K | |
| 97003 | <1% | 2,318 | $16K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 166 | $16K |
| 83540 | <1% | 15,575 | $16K | |
| 87517 | <1% | 2,066 | $15K | |
| 96402 | <1% | 2,072 | $15K | |
| 73700 | <1% | 306 | $15K | |
| 87529 | <1% | 1,245 | $15K | |
| 82043 | <1% | 15,981 | $15K | |
| 93798 | <1% | 1,947 | $14K | |
| 90651 | <1% | 224 | $14K | |
| 80069 | <1% | 10,535 | $14K | |
| 88342 | <1% | 3,632 | $14K | |
| L3260 | Surgical boot/shoe, each | <1% | 605 | $14K |
| 0250 | <1% | 23,037 | $14K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 14 | $14K |
| 0081A | <1% | 347 | $14K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 1,347 | $14K |
| X4303 | <1% | 208 | $13K | |
| 90750 | <1% | 453 | $13K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 677 | $13K |
| 78306 | <1% | 478 | $13K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,993 | $13K |
| 86038 | <1% | 2,282 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,012 | $13K |
| 82607 | <1% | 12,451 | $13K | |
| 96113 | <1% | 170 | $13K | |
| 92133 | <1% | 5,500 | $12K | |
| 84550 | <1% | 17,242 | $12K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,826 | $12K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 617 | $12K |
| 84270 | <1% | 2,674 | $12K | |
| 73060 | <1% | 1,626 | $12K | |
| 76519 | <1% | 1,194 | $11K | |
| 86039 | <1% | 3,422 | $11K | |
| 94010 | <1% | 2,890 | $11K | |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | <1% | 12 | $11K |
| 90686 | <1% | 2,649 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,552 | $11K |
| 86787 | <1% | 1,502 | $11K | |
| 82784 | <1% | 6,458 | $11K | |
| 86225 | <1% | 3,074 | $11K | |
| 0160 | <1% | 154 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 11,915 | $11K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 885 | $11K |
| 51705 | <1% | 775 | $11K | |
| 73120 | <1% | 1,445 | $11K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,343 | $10K |
| 71020 | <1% | 983 | $10K | |
| 92083 | <1% | 4,266 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,749 | $10K |
| 0391 | <1% | 2,793 | $10K | |
| 73660 | <1% | 1,338 | $10K | |
| 91322 | <1% | 69 | $10K | |
| 87070 | <1% | 6,343 | $10K | |
| 73100 | <1% | 1,597 | $10K | |
| 73000 | <1% | 1,217 | $10K | |
| 87808 | <1% | 3,475 | $10K | |
| 86849 | <1% | 5,792 | $10K | |
| 84156 | <1% | 18,366 | $9K | |
| 77073 | <1% | 2,043 | $9K | |
| 92522 | <1% | 1,305 | $9K | |
| 86360 | <1% | 1,061 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,401 | $9K |
| 90619 | <1% | 231 | $9K | |
| 87206 | <1% | 3,740 | $9K | |
| 80164 | <1% | 2,101 | $9K | |
| 90480 | <1% | 347 | $9K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 1,047 | $9K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,694 | $9K |
| 84145 | <1% | 1,320 | $8K | |
| 0300 | <1% | 6,393 | $8K | |
| Z4309 | <1% | 337 | $8K | |
| 77290 | <1% | 195 | $8K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 4,374 | $8K |
| 92020 | <1% | 1,762 | $8K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,986 | $8K |
| 87653 | <1% | 802 | $8K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,956 | $8K |
| 82747 | <1% | 3,607 | $8K | |
| 83615 | <1% | 6,373 | $8K | |
| 93280 | <1% | 1,430 | $8K | |
| 82951 | <1% | 1,756 | $7K | |
| 86304 | <1% | 2,928 | $7K | |
| 72070 | <1% | 755 | $7K | |
| 97161 | <1% | 258 | $7K | |
| 84165 | <1% | 3,350 | $7K | |
| 82465 | <1% | 11,425 | $7K | |
| 86376 | <1% | 1,722 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,186 | $7K |
| 93308 | <1% | 205 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 567 | $7K |
| 96376 | <1% | 3,779 | $7K | |
| 72156 | <1% | 25 | $7K | |
| 86359 | <1% | 1,061 | $7K | |
| 88313 | <1% | 2,138 | $7K | |
| 93458 | <1% | 40 | $7K | |
| 81003 | <1% | 608 | $7K | |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 5,256 | $7K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,796 | $7K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 305 | $7K |
| 87102 | <1% | 2,818 | $7K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 227 | $7K |
| 93246 | <1% | 2,767 | $7K | |
| 87205 | <1% | 6,565 | $7K | |
| 82310 | <1% | 3,716 | $7K | |
| 85007 | <1% | 9,138 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,750 | $7K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,162 | $7K |
| 72082 | <1% | 537 | $7K | |
| 84146 | <1% | 2,288 | $7K | |
| 70480 | <1% | 144 | $7K | |
| 86762 | <1% | 1,837 | $7K | |
| 0761 | <1% | 1,246 | $6K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,669 | $6K |
| 77387 | <1% | 312 | $6K | |
| 76857 | <1% | 548 | $6K | |
| 90670 | <1% | 178 | $6K | |
| 93350 | <1% | 484 | $6K | |
| 82010 | <1% | 1,948 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,540 | $6K |
| 0410 | <1% | 3,461 | $6K | |
| 86147 | <1% | 893 | $6K | |
| 75574 | <1% | 160 | $6K | |
| 77417 | <1% | 836 | $6K | |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 8,256 | $6K |
| 83001 | <1% | 1,522 | $6K | |
| 77049 | <1% | 113 | $5K | |
| 73620 | <1% | 934 | $5K | |
| 96368 | <1% | 840 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 47 | $5K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 75 | $5K |
| 82670 | <1% | 1,031 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,286 | $5K |
| 86146 | <1% | 396 | $5K | |
| 92015 | Determination of refractive state | <1% | 2,167 | $5K |
| 90732 | <1% | 246 | $5K | |
| 92136 | <1% | 543 | $5K | |
| 83520 | <1% | 1,281 | $5K | |
| 83013 | <1% | 1,637 | $5K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 7,805 | $5K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 97 | $5K |
| 77333 | <1% | 355 | $5K | |
| 0173A | <1% | 118 | $5K | |
| 84480 | <1% | 1,483 | $5K | |
| 0003A | <1% | 116 | $5K | |
| 96549 | <1% | 1,666 | $5K | |
| 96910 | <1% | 270 | $5K | |
| 0637 | <1% | 9,724 | $4K | |
| 86705 | <1% | 1,385 | $4K | |
| 88312 | <1% | 3,365 | $4K | |
| 70487 | <1% | 50 | $4K | |
| 84445 | <1% | 320 | $4K | |
| 80177 | <1% | 959 | $4K | |
| 82533 | <1% | 1,171 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 434 | $4K |
| X4530 | <1% | 85 | $4K | |
| 90746 | <1% | 435 | $4K | |
| 86593 | <1% | 2,781 | $4K | |
| 82247 | <1% | 3,025 | $4K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 900 | $4K |
| 86431 | <1% | 2,796 | $4K | |
| 80197 | <1% | 3,180 | $4K | |
| 83718 | <1% | 1,448 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 156 | $4K |
| 0301 | <1% | 12,353 | $4K | |
| 86709 | <1% | 1,259 | $4K | |
| 83921 | <1% | 1,600 | $4K | |
| 74220 | <1% | 364 | $4K | |
| 93242 | <1% | 1,186 | $4K | |
| 81002 | <1% | 2,672 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,986 | $3K |
| 82024 | <1% | 545 | $3K | |
| 82140 | <1% | 911 | $3K | |
| 86800 | <1% | 610 | $3K | |
| 92526 | <1% | 330 | $3K | |
| 73070 | <1% | 370 | $3K | |
| 86364 | <1% | 1,418 | $3K | |
| 90662 | <1% | 337 | $3K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 255 | $3K |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 156 | $3K |
| 86200 | <1% | 1,607 | $3K | |
| Z4302 | <1% | 250 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,136 | $3K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,231 | $3K |
| 84432 | <1% | 577 | $3K | |
| 83521 | <1% | 2,070 | $3K | |
| 86923 | <1% | 1,181 | $3K | |
| 86703 | <1% | 1,019 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,540 | $3K |
| 80306 | <1% | 406 | $3K | |
| 72146 | <1% | 37 | $3K | |
| 88173 | <1% | 1,565 | $3K | |
| 88304 | <1% | 1,934 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 312 | $3K |
| 0171 | Inj, epinephrine (belcher) | <1% | 1,259 | $3K |
| 99606 | <1% | 72 | $3K | |
| 99152 | <1% | 875 | $3K | |
| 92235 | <1% | 231 | $3K | |
| 87149 | <1% | 210 | $3K | |
| 76604 | <1% | 145 | $3K | |
| 86381 | <1% | 577 | $3K | |
| 83002 | <1% | 806 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,626 | $3K |
| 71271 | <1% | 97 | $3K | |
| 0053A | <1% | 63 | $3K | |
| 80299 | <1% | 504 | $2K | |
| 85045 | <1% | 2,582 | $2K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 2,197 | $2K |
| 90675 | <1% | 22 | $2K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 111 | $2K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 249 | $2K |
| H0033 | Oral medication administration, direct observation | <1% | 487 | $2K |
| 87210 | <1% | 1,119 | $2K | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 3,279 | $2K |
| 86696 | <1% | 503 | $2K | |
| 86695 | <1% | 503 | $2K | |
| 93288 | <1% | 1,001 | $2K | |
| 73200 | <1% | 58 | $2K | |
| 97113 | <1% | 254 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 453 | $2K |
| 82232 | <1% | 804 | $2K | |
| 0112A | <1% | 51 | $2K | |
| 84075 | <1% | 3,895 | $2K | |
| 97162 | <1% | 130 | $2K | |
| 88360 | <1% | 508 | $2K | |
| 85613 | <1% | 717 | $2K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 50 | $2K |
| 88307 | <1% | 882 | $2K | |
| 0111A | <1% | 46 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 206 | $2K |
| 86003 | <1% | 281 | $2K | |
| 87634 | <1% | 101 | $2K | |
| 0272 | <1% | 3,309 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 68 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 16,834 | $2K |
| 83993 | <1% | 415 | $2K | |
| 0370 | <1% | 2,427 | $2K | |
| 86308 | <1% | 824 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,258 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,539 | $2K |
| 93979 | <1% | 195 | $2K | |
| 91200 | <1% | 370 | $2K | |
| 86015 | <1% | 695 | $2K | |
| 94644 | <1% | 230 | $2K | |
| 70360 | <1% | 232 | $2K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 917 | $2K |
| 73600 | <1% | 244 | $2K | |
| 80074 | <1% | 170 | $2K | |
| 82977 | <1% | 1,257 | $2K | |
| 86301 | <1% | 456 | $2K | |
| 0516 | <1% | 149 | $2K | |
| 87449 | <1% | 738 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 838 | $2K |
| 0762 | <1% | 433 | $2K | |
| 84132 | <1% | 3,986 | $2K | |
| 90734 | <1% | 154 | $1K | |
| 76937 | <1% | 1,188 | $1K | |
| 76706 | <1% | 83 | $1K | |
| 93923 | <1% | 109 | $1K | |
| 84155 | <1% | 3,302 | $1K | |
| 77399 | <1% | 196 | $1K | |
| 96111 | <1% | 13 | $1K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 153 | $1K |
| 76882 | <1% | 439 | $1K | |
| 84402 | <1% | 296 | $1K | |
| 87420 | <1% | 35 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,323 | $1K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 175 | $1K |
| 87075 | <1% | 886 | $1K | |
| Z4300 | <1% | 12 | $1K | |
| 87338 | <1% | 2,452 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 409 | $1K |
| 80178 | <1% | 617 | $1K | |
| 84166 | <1% | 582 | $1K | |
| 86256 | <1% | 443 | $1K | |
| 0352 | <1% | 2,720 | $1K | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 492 | $1K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,629 | $1K |
| 74160 | <1% | 28 | $1K | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | <1% | 247 | $1K |
| 0013A | <1% | 27 | $1K | |
| 72192 | <1% | 26 | $1K | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 371 | $1K |
| 82040 | <1% | 1,990 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 335 | $1K |
| 90688 | <1% | 103 | $1K | |
| 94150 | <1% | 732 | $1K | |
| 87493 | <1% | 428 | $999.52 | |
| 87324 | <1% | 614 | $998.80 | |
| 86036 | <1% | 361 | $989.80 | |
| 90656 | <1% | 165 | $987.35 | |
| 70543 | <1% | 24 | $982.37 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,880 | $971.49 |
| 72157 | <1% | 24 | $965.81 | |
| 11721 | <1% | 1,338 | $930.70 | |
| 82365 | <1% | 167 | $883.30 | |
| 86677 | <1% | 248 | $871.77 | |
| 92552 | <1% | 106 | $869.89 | |
| 75635 | <1% | 12 | $868.46 | |
| 76942 | <1% | 150 | $847.47 | |
| 0720 | <1% | 1,551 | $846.65 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 309 | $821.93 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 17 | $820.95 |
| 97598 | <1% | 47 | $754.44 | |
| 82390 | <1% | 386 | $742.25 | |
| 86812 | <1% | 107 | $737.14 | |
| A9520 | Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries | <1% | 168 | $730.31 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 483 | $714.75 |
| 78264 | <1% | 24 | $702.96 | |
| 86765 | <1% | 249 | $695.05 | |
| 82507 | <1% | 102 | $691.88 | |
| 74181 | <1% | 14 | $688.71 | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 34 | $687.03 |
| 87902 | <1% | 12 | $686.52 | |
| 82103 | <1% | 203 | $677.99 | |
| 86735 | <1% | 232 | $668.17 | |
| 86922 | <1% | 102 | $661.40 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 348 | $649.38 |
| 86255 | <1% | 193 | $643.49 | |
| 84154 | <1% | 225 | $638.18 | |
| 73522 | <1% | 24 | $632.73 | |
| 86334 | <1% | 144 | $624.25 | |
| 0320 | <1% | 4,599 | $624.13 | |
| 94761 | <1% | 3,397 | $623.94 | |
| 82150 | <1% | 439 | $623.31 | |
| 0351 | <1% | 2,002 | $620.82 | |
| 83721 | <1% | 731 | $620.26 | |
| 92555 | <1% | 108 | $619.08 | |
| 82785 | <1% | 333 | $611.53 | |
| X3920 | <1% | 12 | $599.64 | |
| 72190 | <1% | 84 | $594.80 | |
| 83014 | <1% | 1,637 | $585.20 | |
| 74246 | <1% | 67 | $584.46 | |
| 0324 | <1% | 6,097 | $576.58 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 304 | $571.29 |
| 0340 | <1% | 374 | $568.27 | |
| 0481 | <1% | 2,616 | $562.84 | |
| 82553 | <1% | 245 | $557.72 | |
| 94626 | <1% | 193 | $542.53 | |
| 0306 | <1% | 8,687 | $534.77 | |
| 0730 | <1% | 7,755 | $529.39 | |
| 95806 | <1% | 754 | $523.68 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 69 | $522.93 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 103 | $522.83 |
| 0420 | <1% | 6,201 | $515.73 | |
| 81050 | <1% | 1,031 | $501.82 | |
| 94618 | <1% | 72 | $488.11 | |
| 82272 | <1% | 350 | $452.15 | |
| 83021 | <1% | 74 | $437.55 | |
| 82985 | <1% | 692 | $435.95 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 163 | $428.89 |
| 84300 | <1% | 747 | $426.33 | |
| 99195 | <1% | 268 | $423.23 | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 267 | $422.23 |
| 76000 | <1% | 218 | $415.28 | |
| 82627 | <1% | 87 | $412.02 | |
| 0460 | <1% | 3,726 | $403.05 | |
| 11043 | <1% | 40 | $376.06 | |
| 88172 | <1% | 363 | $374.48 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 265 | $363.92 |
| 11056 | <1% | 119 | $360.46 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 8,310 | $359.35 |
| 93289 | <1% | 187 | $358.43 | |
| 87329 | <1% | 244 | $356.04 | |
| 87400 | <1% | 109 | $355.18 | |
| J2598 | Injection, vasopressin, 1 unit | <1% | 13 | $351.93 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 25 | $342.79 |
| 82945 | <1% | 1,063 | $340.85 | |
| 29075 | <1% | 300 | $336.87 | |
| 72220 | <1% | 56 | $335.33 | |
| 71010 | <1% | 129 | $325.61 | |
| 94664 | <1% | 113 | $325.46 | |
| 83945 | <1% | 102 | $323.68 | |
| 93296 | <1% | 41 | $316.81 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 45 | $312.65 |
| 87272 | <1% | 178 | $311.10 | |
| 0310 | <1% | 1,660 | $308.88 | |
| 84157 | <1% | 1,020 | $304.21 | |
| 76514 | <1% | 590 | $299.43 | |
| 73650 | <1% | 52 | $295.26 | |
| 0341 | <1% | 192 | $288.56 | |
| 82340 | <1% | 263 | $286.27 | |
| 0311 | <1% | 220 | $283.00 | |
| 66982 | <1% | 12 | $280.00 | |
| 89051 | <1% | 937 | $278.28 | |
| 84478 | <1% | 244 | $265.56 | |
| 82239 | <1% | 31 | $262.08 | |
| 77001 | <1% | 152 | $251.74 | |
| 83930 | <1% | 185 | $249.67 | |
| 92229 | <1% | 194 | $248.69 | |
| 0305 | <1% | 12,400 | $244.77 | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 39 | $243.84 |
| 93041 | <1% | 152 | $241.44 | |
| 0350 | <1% | 1,538 | $229.55 | |
| 76885 | <1% | 13 | $226.14 | |
| 99157 | <1% | 13 | $217.81 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 280 | $217.01 |
| 88300 | <1% | 431 | $216.20 | |
| 51784 | <1% | 12 | $210.15 | |
| 90636 | <1% | 13 | $206.00 | |
| G0206 | Diagnostic mammography, including computer-aided detection (cad) when performed; unilateral | <1% | 46 | $204.32 |
| 95812 | <1% | 16 | $202.89 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 365 | $197.49 |
| 83986 | <1% | 273 | $194.65 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 69 | $194.47 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 29 | $193.78 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | <1% | 33 | $192.48 |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 50 | $189.26 |
| 84425 | <1% | 80 | $188.70 | |
| 29405 | <1% | 120 | $185.27 | |
| 84681 | <1% | 54 | $178.30 | |
| 43235 | <1% | 378 | $173.99 | |
| 81206 | <1% | 34 | $173.40 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 77 | $168.38 |
| 0297T | <1% | 607 | $164.97 | |
| 84133 | <1% | 116 | $161.70 | |
| 88142 | <1% | 181 | $158.55 | |
| 0296T | <1% | 607 | $153.36 | |
| 87184 | <1% | 123 | $153.31 | |
| 72072 | <1% | 12 | $149.52 | |
| 85018 | <1% | 297 | $140.83 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,359 | $137.82 |
| 85597 | <1% | 13 | $136.85 | |
| 82330 | <1% | 51 | $127.51 | |
| 92025 | <1% | 122 | $123.04 | |
| 82436 | <1% | 102 | $122.92 | |
| C1729 | Catheter, drainage | <1% | 945 | $121.34 |
| 81208 | <1% | 12 | $120.14 | |
| 83498 | <1% | 15 | $119.65 | |
| 0307 | <1% | 6,320 | $119.38 | |
| 99607 | <1% | 15 | $117.12 | |
| 51702 | <1% | 44 | $115.84 | |
| 74019 | <1% | 12 | $115.34 | |
| 82671 | <1% | 43 | $114.84 | |
| 74230 | <1% | 44 | $109.01 | |
| 82085 | <1% | 70 | $106.30 | |
| 84392 | <1% | 90 | $105.36 | |
| 86694 | <1% | 27 | $104.10 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 318 | $102.41 |
| 29065 | <1% | 40 | $100.95 | |
| 80185 | <1% | 31 | $97.75 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 78 | $93.53 |
| 84105 | <1% | 90 | $91.92 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 56 | $83.55 |
| 80175 | <1% | 40 | $82.46 | |
| 29580 | <1% | 210 | $79.00 | |
| 84244 | <1% | 27 | $78.20 | |
| 0430 | <1% | 4,447 | $77.66 | |
| 80156 | <1% | 14 | $77.51 | |
| 84560 | <1% | 90 | $76.32 | |
| 83935 | <1% | 101 | $75.73 | |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 44 | $74.28 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 17 | $74.03 |
| 82088 | <1% | 13 | $72.44 | |
| 81207 | <1% | 12 | $72.30 | |
| 0402 | <1% | 3,197 | $71.22 | |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 186 | $60.29 |
| 71100 | <1% | 12 | $55.58 | |
| 74000 | <1% | 35 | $54.84 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 507 | $53.81 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 49 | $51.84 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 473 | $51.02 |
| 92060 | <1% | 50 | $46.81 | |
| 82525 | <1% | 25 | $44.12 | |
| 80162 | <1% | 16 | $40.80 | |
| 84630 | <1% | 41 | $40.48 | |
| 88302 | <1% | 52 | $40.04 | |
| 0636 | <1% | 511 | $39.22 | |
| 0302 | <1% | 5,794 | $38.02 | |
| 93283 | <1% | 27 | $36.65 | |
| C2627 | Catheter, suprapubic/cystoscopic | <1% | 213 | $36.57 |
| 0459 | <1% | 27 | $34.10 | |
| 85384 | <1% | 17 | $33.79 | |
| 0489 | <1% | 397 | $32.71 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 12 | $31.51 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 576 | $29.85 |
| 51798 | <1% | 70 | $28.66 | |
| 87101 | <1% | 37 | $27.75 | |
| 87280 | <1% | 19 | $26.52 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,433 | $25.20 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 30 | $24.96 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 413 | $22.76 |
| 0611 | <1% | 758 | $22.11 | |
| 45381 | <1% | 62 | $21.43 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 83 | $20.83 |
| 87341 | <1% | 12 | $16.58 | |
| 83090 | <1% | 12 | $14.99 | |
| 86021 | <1% | 13 | $13.51 | |
| 12001 | <1% | 26 | $12.36 | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 278 | $11.41 |
| 89060 | <1% | 39 | $8.04 | |
| 0258 | <1% | 336 | $7.37 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 30 | $7.28 |
| 88311 | <1% | 65 | $6.87 | |
| L1902 | Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf | <1% | 88 | $3.95 |
| 85008 | <1% | 44 | $0.42 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,492 | $0.40 |
| 90611 | <1% | 107 | $0.36 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 52 | $0.11 |
| 0771 | <1% | 312 | $0.07 | |
| 80324 | 0% | 1,586 | $0.00 | |
| 0612 | Calcium glucon (wg critical) | 0% | 169 | $0.00 |
| 0371 | 0% | 284 | $0.00 | |
| 96040 | 0% | 168 | $0.00 | |
| 80329 | 0% | 948 | $0.00 | |
| 0440 | 0% | 1,202 | $0.00 | |
| J0706 | Injection, caffeine citrate, 5 mg | 0% | 50 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 136 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 496 | $0.00 |
| 0801 | 0% | 613 | $0.00 | |
| 0610 | 0% | 577 | $0.00 | |
| 99243 | 0% | 206 | $0.00 | |
| 0271 | 0% | 248 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 154 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 104 | $0.00 |
| 80050 | General health panel | 0% | 218 | $0.00 |
| 99406 | 0% | 25 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 64 | $0.00 |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | 0% | 39 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 224 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 220 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 84 | $0.00 |
| 81229 | 0% | 12 | $0.00 | |
| 80349 | 0% | 15 | $0.00 | |
| 0383 | 0% | 35 | $0.00 | |
| 86316 | 0% | 23 | $0.00 | |
| 99460 | 0% | 13 | $0.00 | |
| 52356 | 0% | 12 | $0.00 | |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 29 | $0.00 |
| 11055 | 0% | 14 | $0.00 | |
| 0409 | 0% | 14 | $0.00 | |
| 0255 | 0% | 46 | $0.00 | |
| 80320 | 0% | 26 | $0.00 | |
| 80346 | 0% | 118 | $0.00 | |
| 80361 | 0% | 178 | $0.00 | |
| 0278 | 0% | 968 | $0.00 | |
| 0390 | 0% | 1,084 | $0.00 | |
| 11750 | 0% | 27 | $0.00 | |
| 10005 | 0% | 29 | $0.00 | |
| 83835 | 0% | 13 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 67 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 208 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 535 | $0.00 |
| 49083 | 0% | 286 | $0.00 | |
| 0412 | 0% | 87 | $0.00 | |
| 87328 | 0% | 19 | $0.00 | |
| 0312 | 0% | 14 | $0.00 | |
| G0204 | Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral | 0% | 81 | $0.00 |
| 99001 | 0% | 24 | $0.00 | |
| 58558 | 0% | 12 | $0.00 | |
| 0210 | 0% | 45 | $0.00 | |
| 1159F | 0% | 42 | $0.00 | |
| 93926 | 0% | 16 | $0.00 | |
| 0172 | 0% | 15 | $0.00 | |
| 0200 | 0% | 12 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLORENZ, PAUL (CHIEF EXECUTIVE OFFICER)
Parent organizationCOUNTY OF SANTA CLARA
| Provider | Location | Paid |
|---|---|---|
| County of Santa Clara | San Jose, CA | $175.86M |
| County of Santa Clara | San Jose, CA | $132.37M |
| County of Santa Clara | San Jose, CA | $127.88M |
| County of Santa Clara | San Jose, CA | $106.57M |
| County of Santa Clara | San Jose, CA | $101.97M |
| County of Santa Clara | Sunnyvale, CA | $70.54M |
| County of Santa Clara | Gilroy, CA | $65.23M |
| County of Santa Clara | Milpitas, CA | $53.78M |
| County of Santa Clara | San Jose, CA | $21.24M |
| County of Santa Clara | San Jose, CA | $20.55M |
| County of Santa Clara | San Jose, CA | $7.82M |
| County of Santa Clara | San Jose, CA | $5.07M |
| County of Santa Clara | San Jose, CA | $2.19M |
| County of Santa Clara | San Jose, CA | $1.28M |
| County of Santa Clara | San Jose, CA | $1.05M |
| County of Santa Clara | San Jose, CA | $900K |
| County of Santa Clara | San Jose, CA | $358K |
| County of Santa Clara | San Jose, CA | $42K |
| County of Santa Clara | Sunnyvale, CA | $38K |
| County of Santa Clara | San Jose, CA | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.